Please try another search
Trevena, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV734, a small molecule G protein biased ligand of the MOR, which has completed phase I studies for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain. Trevena, Inc. was incorporated in 2007 and is headquartered in Chesterbrook, Pennsylvania.
Name | Age | Since | Title |
---|---|---|---|
Robert J. Lefkowitz | 77 | - | Member of Scientific Advisory Board |
John L. LaMattina | 71 | 2009 | Member of the Scientific Advisory Board |
Robert R. Ruffolo | 70 | 2009 | Member of the Scientific Advisory Board |
Barbara Yanni | 69 | 2014 | Independent Director |
Howard A. Rockman | - | - | Scientific Founder, Consultant and Member of Scientific Advisory Board |
Carrie L. Bourdow | 60 | 2015 | President, CEO & Chairman |
Scott N. Braunstein | 60 | 2018 | Lead Independent Director |
Jason R. Nunn | 53 | 2013 | Independent Director |
Anne M. Phillips | 69 | 2014 | Independent Director |
William K. Schmidt | 73 | - | Member of Scientific Advisory Board |
Marvin H. Johnson | 61 | 2021 | Independent Director |
Mark H. N. Corrigan | 66 | 2023 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review